What It Takes to Reach the Patient

A patient can leave an appointment with the right prescription and never fill it. A laboratory can identify a pathogen within hours while therapy remains unchanged. A continuous glucose monitor (CGM) can produce hundreds of readings for someone who has no idea what to do with them.

Those moments say a great deal about where progress in health care can slow down. Evidence may support a treatment or technology, yet the patient still has to gain access to it, understand it, and receive the follow-up required to use it safely. The articles in this issue of Pharmacy Practice in Focus: Health Systems examine what happens during that part of the journey.

For some patients, the first obstacle is cost. The pharmacist-led initiative featured in this issue focuses on enrolling Medicare-eligible patients in a state pharmaceutical assistance program. Affordability concerns often surface during medication reconciliation or discharge planning when a patient finally says that a prescription costs too much. From there, someone has to determine whether the patient qualifies for assistance, explain the requirements, help complete the enrollment, and follow up. A treatment plan that appeared settled in the hospital may depend on what happens during those conversations.

Heart failure care brings its own set of practical decisions. Guideline-directed medical therapy may involve starting or adjusting several medications during a single hospitalization. The care team must consider the patient’s clinical status, tolerance, timing, and postdischarge monitoring. The electronic health record pathway examined in this issue brings that guidance into the team’s daily workflow and evaluates its effect on recommended therapy and patient outcomes.

Health information is also reaching patients in places where a clinician may not be present. In 2024, the FDA cleared the first over-the-counter CGM for adults who do not use insulin. In June 2026, the indication expanded to include individuals 2 years and older who do not use insulin.¹

A CGM can help someone recognize patterns related to meals and activity. It can also produce a volume of information that is difficult to interpret without context. A single reading may cause unnecessary concern, whereas a meaningful trend may go unnoticed. Pharmacists can explain what the device measures, where its limitations lie, and when the results deserve further discussion with a clinician.

Vaccine questions arrive from many directions. A patient may have heard one recommendation from one clinician, another on the news, and something entirely different from a relative or a social media post. The conversation usually becomes more productive when we start by asking what is actually causing the concern. Pharmacists need reliable resources and a current understanding of the evidence. We also need to explain recommendations clearly, correct misinformation directly, and give patients room to ask questions they may be reluctant to raise.

In South Florida, I see how quickly a community’s needs can change. Our population continues to grow, and the patients we serve bring different languages, cultures, health histories, and experiences with care. Research has to keep pace with that change. We need to know whether the people included in clinical studies reflect those who will ultimately receive the treatment. That consideration reaches into vaccine conversations, medication use, consumer health technology, and advanced therapies. Representative research gives clinicians a stronger foundation for decisions made with individual patients.

Familiar medications deserve the same careful attention. Acetaminophen is used throughout acute care, yet determining a maximum daily dose of 4000 mg requires a review of the patient’s condition and any other potential sources of exposure. Levetiracetam raises a separate dosing question when used for early posttraumatic seizure prophylaxis.

The report of cutaneous sensory disturbance during semaglutide-associated weight loss calls attention to a potential adverse effect that many clinicians may not immediately recognize. As more patients use a medication, the range of experiences seen in practice grows. An individual case can provide the first signal that something deserves closer study. Careful observation and documentation allow that experience to inform future care.

Earlier microbiology results give antimicrobial stewardship teams an opportunity to reassess therapy sooner. The result must reach the treating team and prompt a decision on whether treatment should continue, change, or stop. Pharmacists connect the laboratory findings with the medication order. That connection depends on timely communication and a workflow designed to support action.

Cell and gene therapies magnify the clinical and operational demands placed on health systems. The latest landscape report from the American Society of Gene and Cell Therapy and Citeline identified 4487 gene, cell, and RNA therapies in development from preclinical through preregistration.² Their reach extends across oncology, neurologic disease, cardiovascular conditions, and many other areas of medicine.

For health systems, preparation begins long before a product is administered. Teams have to identify appropriate patients, confirm eligibility, complete testing, secure coverage, acquire the therapy, and establish a monitoring plan. Patients experience that process as a series of conversations, appointments, approvals, and clinical decisions. Pharmacy remains involved throughout those steps, helping the program stay connected as the patient moves through it.

Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it. Burnout affects continuity of care, patient access, and the ability to expand clinical services safely. When experienced pharmacists and technicians leave practice, years of knowledge leave with them. Leaders have to look honestly at staffing, workload, technology, administrative demands, and whether pharmacy teams have the capacity to provide the care being asked of them.

When I look across this issue, I keep coming back to how much depends on someone noticing what has not happened yet: the prescription that was never filled, the result that never changed therapy, the patient who has information and no clear next step. Pharmacists see those moments every day, and the articles that follow show how teams are responding to them.

REFERENCES

1. FDA clears first over-the-counter continuous glucose monitor for children. News release. FDA. June 12, 2026. Accessed October 9, 2026. https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor-children

2. American Society of Gene & Cell Therapy. Gene, Cell, & RNA Therapy Landscape Report: Q2 2026 Quarterly Data Report. Citeline; July 2026. Accessed October 9, 2026. https://www.asgct.org/uploads/files/general/Final-ASGCT-Citeline-Q2-2026.pdf